SCHEMBL2263589

SCHEMBL2263589

Cc1ccc(Cn2c(-c3ccc(Oc4cccc(C(C)(C)C)c4)cc3)cc(C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.61
NR1H3 Q13133 4/20 0.61
RXRA P19793 3/20 0.61
AR P10275 4/20 0.39
POLB P06746 1/20 0.36
MEN1 O00255 1/20 0.35
CNR1 P21554 1/20 0.35
GPR183 P32249 1/20 0.35
CNR2 P34972 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 5/20 0.35
GLA P06280 3/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 1/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 5/20 0.34
LMNA P02545 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
PGGT1B P53609 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264600 0.92 NR1H2 (0.60) NR1H2NR1H3RXRAARPOLB
SCHEMBL2263683 0.92 NR1H2 (0.65) NR1H2NR1H3RXRAARMEN1
SCHEMBL2262606 0.91 NR1H2 (0.61) NR1H2NR1H3RXRAARMEN1
SCHEMBL2264390 0.90 NR1H2 (0.62) NR1H2NR1H3RXRAARMEN1
SCHEMBL2263493 0.90 NR1H2 (0.62) NR1H2NR1H3RXRAARMEN1
SCHEMBL2266726 0.90 NR1H2 (0.65) NR1H2NR1H3RXRAARPOLB
SCHEMBL2262536 0.89 NR1H2 (0.66) NR1H2NR1H3RXRAARMEN1
SCHEMBL2263366 0.89 NR1H2 (0.61) NR1H2NR1H3RXRAARMEN1
SCHEMBL2264449 0.89 NR1H2 (0.55) NR1H2NR1H3RXRAARALDH1A1
SCHEMBL4897339 0.89 NR1H2 (0.61) NR1H2NR1H3RXRAARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 NR1H2 1/4885NR1H3 2/4885RXRA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.